{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:07:26Z","timestamp":1784700446216,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) complicated by immune thrombotic thrombocytopenic purpura (iTTP) and lupus cerebritis is a severe clinical event. Standard therapeutic plasma exchange (TPE) frequently fails in this context due to a \u201crebound effect\u201d, as it clears circulating antibodies but spares the intravascular reservoir of autoreactive lymphocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 30-year-old male presented with refractory SLE, severe iTTP (platelet count: 5.00 \u00d7 10^9\/L; ADAMTS13 activity: 1.49%), and imaging-confirmed lupus cerebritis. The patient underwent a unique \u201cA-B-A\u201d treatment trajectory. While five sessions of standard TPE at an outside facility did not fully halt the hyper-regenerative hemolysis and CNS progression, the implementation of an optimized lymphoplasmapheresis (LPE) regimen at our center induced rapid hematological remission, progressive radiological resolution of brain lesions, and the alleviation of immune-mediated renal injury, culminating in restored renal function and decreased proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Mechanistic insights<\/jats:title>\n                    <jats:p>The optimized LPE protocol utilized a novel dual-parameter modulation (synchronizing blood drawing speed and hematocrit) to precisely extract the pathogenic lymphocyte-rich buffy coat without exacerbating anemia. Paired quantitative analysis of the patient\u2019s peripheral blood and LPE effluent provided direct evidence of substantial cytokine (e.g., IL-10, IL-8, TNF-\u03b1) clearance. This facilitated the rapid seroconversion of antinuclear and anti-dsDNA antibodies. Furthermore, this targeted cellular depletion reduced the required allogeneic replacement plasma volume by up to 50% compared with standard TPE, conserving blood bank resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Optimized LPE may interrupt the autoimmune cascade by simultaneously reducing circulating humoral mediators and lymphocyte-rich cellular components. This single-case observation supports its potential as a resource-sparing rescue strategy for refractory autoimmune microangiopathy, although further validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1841313","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:56:30Z","timestamp":1784699790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reversal of refractory systemic lupus erythematosus-associated immune thrombotic thrombocytopenic purpura and cerebritis via optimized lymphoplasmapheresis: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Chi-E","family":"Qiu","sequence":"first","affiliation":[{"name":"Hematology Department, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hematology Department, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Hematology Department, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongdan","family":"Ma","sequence":"additional","affiliation":[{"name":"Hematology Department, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of radiology, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Northeast Yunnan Central Hospital","place":["Zhaotong, Yunnan, China"]},{"name":"Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5045\/br.2022.2022005","article-title":"Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura","volume":"57","author":"Bae","year":"2022","journal-title":"Blood Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13730-021-00627-5","article-title":"Thrombotic microangiopathy in a patient with systemic lupus erythematosus and anti-factor H autoantibodies","volume":"11","author":"Figueiredo","year":"2022","journal-title":"CEN Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08820-7","article-title":"B cell aberrance in lupus: the ringleader and the solution","volume":"62","author":"Nie","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.2003703","article-title":"Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura","volume":"14","author":"Pavenski","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70628","article-title":"Lymphoplasmapheresis for steroid-refractory neuromyelitis optica spectrum disorder: a real-world multicenter study in China","volume":"31","author":"Zeng","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28422","article-title":"Comparison of efficacy between lymphoplasmapheresis and plasma exchange in myasthenic crisis","volume":"72","author":"Duan","year":"2025","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J Thromb Haemost JTH"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1700907","article-title":"EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura","volume":"16","author":"Escribano-Serrat","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.757192","article-title":"Emerging concepts in immune thrombotic thrombocytopenic purpura","volume":"12","author":"Laghmouchi","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1944102","article-title":"Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy","volume":"14","author":"Elverdi","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11830-y","article-title":"Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"270","author":"Neuman","year":"2023","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxad011","article-title":"A case of systemic lupus erythematosus having concurrent Evans syndrome and acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Motoyama","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103918","article-title":"Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation","volume":"63","author":"Pitk\u00e4nen","year":"2024","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.04.012","article-title":"When targeted therapies alleviate the burden of TPE: the example of immune-mediated TTP","volume":"58","author":"Picod","year":"2019","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/17474086.2024.2318347","article-title":"Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons","volume":"17","author":"Segu\u00ed","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.02.011","article-title":"Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura","volume":"21","author":"Underwood","year":"2023","journal-title":"J Thromb Haemost JTH"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000533736","article-title":"Challenges for plasma-derived medicinal products","volume":"50","author":"Moog","year":"2023","journal-title":"Transfus Med Hemother Off Organ Dtsch Ges Transfusionsmedizin Immunhamatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-024-01773-y","article-title":"Hypogammaglobulinemia and infection events in patients with autoimmune diseases treated with rituximab: 10 years real-life experience","volume":"44","author":"Nie","year":"2024","journal-title":"J ClinImmunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.757841","article-title":"Lymphoplasma exchange improves myasthenia gravis exacerbations: a retrospective study in a Chinese center","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1018509","article-title":"Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis","volume":"13","author":"Duan","year":"2022","journal-title":"Front Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:56:32Z","timestamp":1784699792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1841313"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1841313","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1841313"}}